Industry Leaders Ascensia Diabetes Care And Glooko Announce Diabetes Technology Partnership To Deliver Integrated Diabetes Data Solutions

Ascensia Diabetes Care and Glooko, Inc recently announced a global technology partnership designed to bring together their state-of-the-art diabetes management solutions, and improve diabetes data management and analytics. This collaboration includes integration of Glooko’s Diabetes Data Management Platform and Ascensia’s CONTOUR NEXT ONE and CONTOUR PLUS ONE blood glucose monitoring systems. The integration of these solutions will allow people with diabetes and health care professionals to access and analyze highly accurate blood glucose data at home, on the move and during office visits through the digital platform of their choice.

“Glooko’s Diabetes Data Management Platform has become widely used for both personal and clinical diabetes data analytics and decision support,” said Michael Kloss, CEO of Ascensia Diabetes Care. He continued, “Glooko’s broad distribution into health systems will enable us to easily and seamlessly deliver highly accurate data from our CONTOUR NEXT ONE and CONTOUR PLUS ONE blood glucose monitoring systems to clinicians right in their workflow. By linking our systems to Glooko’s Diabetes Data Management Platform, we want to enable better understanding and analysis of diabetes data, and ultimately help to improve the lives of people with diabetes.”

The integration of these solutions will allow blood glucose data to be accessed by Glooko’s Mobile App and Clinic Data Upload products directly from the CONTOUR NEXT ONE and CONTOUR PLUS ONE meters via Bluetooth connectivity and through an automatic feed via the CONTOUR CLOUD. People with diabetes will be able to view their data both in Glooko’s Mobile and Web Apps, as well as in the CONTOUR DIABETES App from Ascensia. Health care professionals will be able to seamlessly access data from these two Ascensia systems in a way that fits directly into their workflow via the Glooko Clinic Solution.

“The usability and accuracy of the CONTOUR NEXT ONE and CONTOUR PLUS ONE blood glucose monitoring systems from Ascensia Diabetes Care is impressive and we are excited to bring this rich data into the Glooko platform to help both people with diabetes and their health care professionals manage this condition,” said Rick Altinger, Glooko CEO.

The CONTOUR NEXT ONE system recently received 510(k) clearance from the FDA and Ascensia Diabetes Care expects to make this system available in the United States in early 2017. The CONTOUR DIABETES app will be available for download from the Apple App Store (iOS) and Google Play (Android). The CONTOUR NEXT ONE and CONTOUR PLUS ONE systems have been demonstrated to be the two most accurate systems developed by Ascensia Diabetes Care to date, having been shown to deliver remarkable accuracy. In a clinical study, 95% of blood glucose results obtained with CONTOUR NEXT ONE were within 8.4 mg/dL (0.5 mmol/L) or 8.4% of the reference result for subject fingertip tests.¹ In a similar clinical study, 95% of blood glucose results for CONTOUR PLUS ONE were within 8.5 mg/dL (0.5 mmol/L) or 8.5% of the reference result for subject fingertip tests.²

Glooko is a leading population health platform for diabetes management and enables people with diabetes to more easily track and better manage their condition using mobile, web and cloud technology. Glooko’s award-winning mobile health app enables individuals to synchronize their data from a majority of the world’s most popular diabetes and exercise devices including blood glucose meters. Glooko’s population health application enables care teams to remotely support people with diabetes and aims to improve patient satisfaction and outcomes at a lower cost.

This global agreement covers all markets where Glooko and these Ascensia systems are available. The integration between these two solutions is expected to be available for people with diabetes and health care professionals later in 2017.

About Glooko
Glooko is the leading remote patient monitoring platform for diabetes and is trusted by the world’s leaders in diabetes care. Over 4,800 health systems in 27 countries use Glooko’s FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes and to enable diabetes population health for providers. Glooko seamlessly syncs with the world’s most popular diabetes devices and major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. For more information, visit glooko.com.

About Ascensia Diabetes Care
Ascensia Diabetes Care is a global specialist diabetes care company, dedicated to helping people living with diabetes. Our mission is to empower people living with diabetes through innovative solutions that simplify and improve their lives. We use our innovation and specialist expertise in diabetes to develop high quality solutions and tools that make a positive, daily difference for people with diabetes.

Home to the world renowned CONTOUR portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality that help people with diabetes to manage their condition. We are committed to continued research, innovation and development of new products and solutions. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd. Ascensia Diabetes Care products are sold in more than 125 countries. Ascensia Diabetes Care has around 1,700 employees and operations in 38 countries. For more information, visit http://www.ascensia.com.

¹.Christiansen et al. Poster presented at the 15th Annual Meeting of the Diabetes Technology Society, October 22-24, 2015, Bethesda, Maryland.

².Bailey et al. Poster presented at the 15th Annual Meeting of the Diabetes Technology Society, October 22-24, 2015, Bethesda, Maryland.